How Willing Are Patients to Enroll in Cancer Clinical Trials Amid COVID-19 Pandemic?

JAMA Oncology

EMBARGOED FOR RELEASE: 11 A.M. (ET), THURSDAY, NOVEMBER 12, 2020

Media advisory: The full article is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2020.5748?guestAccessKey=eb3eb00a-0ec0-46e5-8841-47048e996328&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=111220

 

What The Study Did: Researchers surveyed a large group of cancer survivors about their attitudes toward trial participation during the COVID-19 pandemic.

Authors: Mark E. Fleury, Ph.D., of the American Cancer Society Cancer Action Network in Washington, D.C., is the corresponding author.

 

(doi:10.1001/jamaoncol.2020.5748)

Editor’s Note: The article includes funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.